Research Analysts Set Expectations for Bruker Q1 Earnings

Bruker Co. (NASDAQ:BRKR) – Zacks Research lowered their Q1 2025 EPS estimates for Bruker in a report issued on Thursday, March 6th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $0.44 for the quarter, down from their prior estimate of $0.52. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q3 2025 earnings at $0.70 EPS, FY2025 earnings at $2.67 EPS, Q2 2026 earnings at $0.70 EPS, Q3 2026 earnings at $0.82 EPS, FY2026 earnings at $3.11 EPS and FY2027 earnings at $3.60 EPS.

A number of other equities research analysts have also weighed in on the stock. Bank of America boosted their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Barclays reduced their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Stifel Nicolaus reduced their target price on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. Guggenheim reissued a “buy” rating on shares of Bruker in a report on Monday, February 24th. Finally, The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a report on Thursday, December 5th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bruker has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Bruker Price Performance

BRKR stock opened at $48.41 on Friday. The company has a 50 day simple moving average of $55.17 and a 200 day simple moving average of $59.20. The stock has a market cap of $7.34 billion, a price-to-earnings ratio of 63.70, a P/E/G ratio of 2.16 and a beta of 1.16. Bruker has a 1 year low of $45.29 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.41%. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Institutional Trading of Bruker

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in Bruker by 21.4% during the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after buying an additional 2,521,904 shares during the last quarter. London Co. of Virginia increased its holdings in Bruker by 78.4% during the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock worth $245,820,000 after buying an additional 1,843,294 shares during the last quarter. State Street Corp increased its holdings in Bruker by 9.6% during the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock worth $250,501,000 after buying an additional 318,808 shares during the last quarter. RTW Investments LP increased its holdings in Bruker by 1.1% during the third quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock worth $240,406,000 after buying an additional 37,024 shares during the last quarter. Finally, Brown Advisory Inc. increased its holdings in Bruker by 10.1% during the fourth quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company’s stock worth $118,806,000 after buying an additional 185,912 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.